Two committees set up to supervise clinical trial:Centre to SC

Image
Press Trust of India New Delhi
Last Updated : Sep 30 2013 | 6:41 PM IST
The Centre today told the Supreme Court that committees have been formed to supervise the regulation of clinical trials of drugs in the country and a new bill containing penal provisions for violation on conduct of trials for untested medicines has already been introduced in Parliament.
In an affidavit filed in the apex court, the Ministry of Health and Family Welfare submitted it is committed to safeguarding the safety and well-being of people subjected to trial.
It said an apex committee, headed by the Health and Family Welfare Secretary, has been formed to supervise the regulation of clinical trials based on the recommendation of the Technical Committee constituted under the chairmanship of the Director General Health Services.
"It is submitted that the government is committeed in its resolve for safeguarding the rights, safety and well-being of the subjects participating in the clinical trials and has been taking sincere and concerted steps in that direction," the affidavit said.
"It is submitted that the Drugs and Cosmetics(Amendment) Bill, 2013 has been introduced in Parliament. The Bill has a separate chapter containing penal provisions for violation and non-compliance of the provisions relating to conduct of the clinical trials," it said.
The Centre also told the apex court that central Drugs Standard Control Organisation (CDSCO) is being expanded and its strength will be increased from 327 posts with 169 drug inspectors to 1102 during the 12the five tear plan.
It said that out of 89 cases of clinical trial death between 2005-12, compensation has been paid in 82 cases so far and the CDSCO is looking into rest of the cases.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 30 2013 | 6:41 PM IST

Next Story